AAAAAA

   
Results: 1-4 |
Results: 4
THE EFFECTS OF EPOPROSTENOL ON DRUG DISPOSITION .1. A PILOT-STUDY OF THE PHARMACOKINETICS OF DIGOXIN WITH AND WITHOUT EPOPROSTENOL IN PATIENTS WITH CONGESTIVE-HEART-FAILURE
Authors: CARLTON LD PATTERSON JH MATTSON CN SCHMITH VD
Citation: Ld. Carlton et al., THE EFFECTS OF EPOPROSTENOL ON DRUG DISPOSITION .1. A PILOT-STUDY OF THE PHARMACOKINETICS OF DIGOXIN WITH AND WITHOUT EPOPROSTENOL IN PATIENTS WITH CONGESTIVE-HEART-FAILURE, Journal of clinical pharmacology, 36(3), 1996, pp. 247-256
THE EFFECTS OF EPOPROSTENOL ON DRUG DISPOSITION .2. A PILOT-STUDY OF THE PHARMACOKINETICS OF FUROSEMIDE WITH AND WITHOUT EPOPROSTENOL IN PATIENTS WITH CONGESTIVE-HEART-FAILURE
Authors: CARLTON LD PATTERSON JH MATTSON CN SCHMITH VD
Citation: Ld. Carlton et al., THE EFFECTS OF EPOPROSTENOL ON DRUG DISPOSITION .2. A PILOT-STUDY OF THE PHARMACOKINETICS OF FUROSEMIDE WITH AND WITHOUT EPOPROSTENOL IN PATIENTS WITH CONGESTIVE-HEART-FAILURE, Journal of clinical pharmacology, 36(3), 1996, pp. 257-264
PHYSIOLOGICAL PHARMACOKINETIC MODELING OF GASTROINTESTINAL BLOOD-FLOWAS A RATE-LIMITING STEP IN THE ORAL ABSORPTION OF DIGOXIN - IMPLICATIONS FOR PATIENTS WITH CONGESTIVE-HEART-FAILURE RECEIVING EPOPROSTENOL
Authors: CARLTON LD POLLACK GM BROUWER KLR
Citation: Ld. Carlton et al., PHYSIOLOGICAL PHARMACOKINETIC MODELING OF GASTROINTESTINAL BLOOD-FLOWAS A RATE-LIMITING STEP IN THE ORAL ABSORPTION OF DIGOXIN - IMPLICATIONS FOR PATIENTS WITH CONGESTIVE-HEART-FAILURE RECEIVING EPOPROSTENOL, Journal of pharmaceutical sciences, 85(5), 1996, pp. 473-477
INTRAVENOUS EPOPROSTENOL SODIUM DOES NOT INCREASE HEPATIC-MICROSOMAL ENZYME-ACTIVITY IN RATS
Authors: CARLTON LD SCHMITH VD BROUWER KLR
Citation: Ld. Carlton et al., INTRAVENOUS EPOPROSTENOL SODIUM DOES NOT INCREASE HEPATIC-MICROSOMAL ENZYME-ACTIVITY IN RATS, Prostaglandins, 50(5-6), 1995, pp. 341-347
Risultati: 1-4 |